Sep 5, 2025

The Weekly Recap 9/5/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

The Weekly Recap 9/5/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

LSI’s-Weekly-Recap-featuring-milestones-from-LSI-Alumni-companies-including-Aortyx-and-Galvanize-Therapeutics

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure $195M in funding, appoint new executives, and much more on the road to LSI Europe ‘25 next week in London (September 7-11).

Aortyx

Received a new patent grant from the China National Intellectual Property Administration for its biomimetic, bioresorbable aortic patch. The achievement completes global IP protection for the device and strengthens the company’s position as it advances toward worldwide commercialization of its endovascular repair platform.

Berlin Heals

Raised more than $5M in an A2 round to advance its C-MIC system, a novel implantable device for heart failure that delivers direct microcurrent therapy. The funding supports a new first-in-man study evaluating a new, less invasive implantation approach designed for outpatient cath lab use and faster recovery.

ClearCam

Appointed thoracic surgeon Dr. Rachel Medbery as its first member of its Medical Advisory Board to support product development and clinical expansion. The move marks a strategic next step as ClearCam scales its ClearScope™ platform and builds a team of clinical partners to guide future innovation in surgical visualization.

Galvanize Therapeutics

Raised $100M in an oversubscribed Series C round led by Sofinnova Partners to expand commercialization and clinical development of its pulsed electric field (PEF) platform. The round coincides with the appointment of Doug Godshall as CEO and supports ongoing progress in oncology and chronic bronchitis with its Aliya PEF and RheOx therapy.

Innitius

Appointed Benjamin Sommerkorn, PhD, as Director of Quality & Regulatory Affairs to lead global regulatory strategy and support clinical and commercial expansion. Dr. Sommerkorn brings FDA experience and deep regulatory expertise to Innitius as it advances next-generation diagnostics in women’s health.

Nurami Medical

Appointed Amirit Oshri-Chai as VP of QA & Regulatory Compliance to support the company’s growth and commercialization efforts. She brings leadership experience from GE Healthcare, Medtronic, and HP, and will play a key role in advancing Nurami’s soft tissue repair technologies, ArtiFascia and ArtiFix.

Nutromics

Raised A$7.5M to advance ICU trials and commercialization of its lab-on-a-patch technology, bringing total funding to A$60M. The platform uses DNA-based biosensors to enable continuous, multi-analyte monitoring, starting with vancomycin, and has the potential to transform diagnostics in critical care and emergency settings.

Pulnovo Medical

Appointed Dr. Francis Duhay as Global Chief Medical Officer to support international growth and clinical advancement of its Pulmonary Artery Denervation (PADN) program. Dr. Duhay, former CMO at Edwards Lifesciences, brings deep expertise in global regulatory strategy and a legacy of leadership in transformative cardiovascular technologies like TAVR.

Samay 

Was named Colombia’s Best Startup of 2025 after rising to the top from over 2,000 applicants in a national competition. The recognition highlights Samay’s global leadership in deep tech innovation and its mission to revolutionize respiratory care through science-driven solutions.

Sutra Medical

Completed the first-in-human implantation of the Sutra Hemi-Valve in a high-risk patient with severe functional mitral regurgitation and posterior leaflet tethering at Waikato Hospital in New Zealand. The transfemoral, trans-septal procedure reduced MR severity and marks a major milestone for Sutra’s novel leaflet replacement system designed for patients unsuitable for surgery or TEER.

Vektor Medical

Appointed Kelly Perez as CFO and SVP of Operations to support scaling the adoption of its non-invasive arrhythmia analysis platform, vMap. Perez brings leadership experience from Omniome, Luxtera, and Sequenom, and will help guide Vektor’s financial and operational strategy.

ViCentra

Raised $85M in an upsized Series D round led by Innovation Industries to scale manufacturing and accelerate the commercialization of Kaleido 2, its next-generation insulin patch pump. Designed as a lifestyle-oriented solution, Kaleido is gaining strong traction across Europe and positions ViCentra for U.S. market entry.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.